Kiromic BioPharma

Kiromic BioPharma

Kiromic BioPharma is a publicly traded biotechnology firm headquartered in Houston, Texas. The company was founded to develop novel cancer immunotherapies and operates as a developmental-stage biopharmaceutical entity, focusing on the discovery and clinical evaluation of allogeneic cell therapies. The company's core strategy centers on its Gamma Delta T-cell platform, which aims to produce off-the-shelf cell therapies that target solid tumors. Kiromic BioPharma's pipeline includes lead candidates such as KIR-100, KIR-101, and KIR-102, targeting indications like ovarian cancer and pancreatic cancer. The firm employs its proprietary Diamond platform, an artificial intelligence-driven discovery system, to identify and engineer therapeutic molecules. Their geographic focus is primarily the United States, with clinical operations based in Houston. As a publicly traded entity, Kiromic BioPharma raises capital through equity offerings and partnerships. The firm reports through SEC filings and has a small team based in Houston. No additional offices, philanthropic foundations, or adjacent vehicles are publicly identified. Recent operational activity includes advancing preclinical and Phase 1 clinical programs for its lead candidates. Kiromic BioPharma's structural differentiator is its focus on allogeneic, off-the-shelf cell therapies, which contrasts with the autologous approach taken by many competitors. This architecture could enable broader patient access and lower manufacturing costs if clinical development succeeds. The company's use of AI in target discovery further distinguishes its R&D process.